Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin

Abstract Background The most recent treatment guidelines for type 2 diabetes (T2D) recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors should be considered preferentially in patients with T2D with either a high cardiovascular risk or with cardiovascular disease (CVD), regardless of their dia...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node, the EMBLEM Investigators
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Cardiovascular disease
Sodium-glucose cotransporter 2 inhibitor
Metformin
Online Access:https://doi.org/10.1186/s12933-021-01352-0

Internet

https://doi.org/10.1186/s12933-021-01352-0

Similar Items